title: Isolated hyperbilirubinemia following standard dose cytosine arabinoside in a patient with relapsed acute myeloid leukemia.
authors.forename: Ozden
authors.initials: O
authors.lastname: Altundag
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
authors.forename: Ismail
authors.initials: I
authors.lastname: Celik
authors.forename: Alev
authors.initials: A
authors.lastname: Turker
authors.forename: Ayse
authors.initials: A
authors.lastname: Kars
mesh_terms: D000208:Acute Disease; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced*; D007951:Leukemia, Myeloid / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D012008:Recurrence
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine